Shanghai Nianxing Industrial Co., Ltd
China
Product Name: AQX-435
Price:
Purity: 98.0%
Stocking Period: 10 Day
Contact: Huang

DC Chemicals Limited
China
Product Name: AQX-435
Price: $Inquiry/250mg $Inquiry/100mg $Inquiry/1g
Purity: 98.0%
Stocking Period: 3 Day
Contact: Tony Cao

1619983-52-6

1619983-52-6 structure

1619983-52-6 structure

Name: AQX-435
Chemical Name: AQX-435
CAS Number: 1619983-52-6
Molecular Formula: C₂₇H₃₄N₂O₄
Molecular Weight: 450.57
Catalog: Signaling Pathways Apoptosis Apoptosis
Create Date: 2021-01-09 00:01:47
Modify Date: 2024-01-09 19:40:06
AQX-435 is a potent SHIP1 activator. AQX-435 reduces PI3K activation downstream of the B-cell receptor (BCR) and induces apoptosis of malignant B cells, and reduces lymphoma growth[1].

Name	AQX-435

Description	AQX-435 is a potent SHIP1 activator. AQX-435 reduces PI3K activation downstream of the B-cell receptor (BCR) and induces apoptosis of malignant B cells, and reduces lymphoma growth[1].
Related Catalog	Signaling Pathways >> Apoptosis >> Apoptosis Signaling Pathways >> Metabolic Enzyme/Protease >> Phosphatase Research Areas >> Inflammation/Immunology
In Vitro	AQX-435 reduces CLL cell viability in a dose-dependent manner[1]. AQX-435 (5-30 µM; 24 hours)-induced apoptosis was mediated via caspases since AQX435 induced PARP cleavage[1]. AQX-435 effectively inhibits PI(3,4,5)P3-mediated signaling downstream of the BCR in CLL and DLBCL cells[1]. AQX-435 and ibrutinib combine effectively to enhanced inhibition of BCR signaling. AQX-435 induced TMD8 cell apoptosis in vitro with an IC50 of ~2 µM. AQX-435 reduces anti-IgM-induced AKT phosphorylation and induces apoptosis in DLBCL cells[1]. Cell Viability Assay[1] Cell Line: Chronic lymphocytic leukemia (CLL) cells Concentration: 5-30 µM Incubation Time: 24 hours Result: Reduced CLL cell viability in a dose-dependent manner.
In Vivo	AQX-435 (10 mg/kg; i.p.; 5 days) significantly reduced the volume of TMD8 tumors[1]. AQX-435 (50 mg/kg; ip) inhibits DLBCL PDX tumors growth[1]. AQX-435 reduced AKT phosphorylation and growth of DLBCL in vivo and cooperated with ibrutinib for tumor growth inhibition[1]. Animal Model: NOD.Cg-Prkdc scidIl2rgtm1Wjl/SzJ mice (NSG mice) (TMD8 tumors)[1] Dosage: 10 mg/kg Administration: I.p.; in 7-day cycles each comprising 5 days of AQX-435 followed by 2 days with no drug Result: Reduced the volume of TMD8 tumors.
References	[1]. Lyoyd F. MACKENZIE, et al. Ship1 modulators and methods related thereto.WO2014110036A1.

Molecular Formula	C₂₇H₃₄N₂O₄
Molecular Weight	450.57